Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, H-1313, New York, NY 10065, USA.
Cancer Control. 2011 Jan;18(1):44-51. doi: 10.1177/107327481101800106.
The management of ovarian cancer includes a combination of surgery and chemotherapy. The majority of clinical trials have historically addressed questions pertaining to the selection, dosing, and schedule of chemotherapy agents.
In this report, a comprehensive review of the major clinical trials in ovarian cancer is performed. The increasing data and clinical experience in the management of ovarian cancer, as it sets the stage for currently active protocols and future clinical trial design, are emphasized.
Paclitaxel plus carboplatin is the primary intravenous treatment strategy in the front-line setting. Recent data show an improvement in overall survival for intravenous dose-dense treatment. Multiple randomized controlled trials support the use of intraperitoneal treatment. For recurrent disease, a growing number of new agents including targeted therapeutics are now available. Increasingly, surgical approach, biologic targets, and quality of life endpoints are included in clinical trial design.
Over the last several decades, clinical trials have defined the current therapeutic approach for ovarian cancer. Paclitaxel with a platinum-based agent is currently the preferred front-line therapy, with encouraging data to support either dose-dense or intraperitoneal drug delivery. Future trials will determine the role of biologic agents and vaccine therapies, as well as their impact on quality of life.
卵巢癌的治疗包括手术和化疗的综合应用。历史上，大多数临床试验都针对化疗药物的选择、剂量和方案提出了问题。
本报告对卵巢癌的主要临床试验进行了全面回顾。强调了在当前活跃的方案和未来临床试验设计中，卵巢癌管理方面不断增加的数据和临床经验。
紫杉醇联合卡铂是一线治疗的主要静脉治疗策略。最近的数据显示，静脉剂量密集治疗可提高总生存率。多项随机对照试验支持腹腔内治疗的应用。对于复发性疾病，越来越多的新型药物，包括靶向治疗药物，现已上市。越来越多的临床试验开始将手术方法、生物靶点和生活质量终点纳入设计。
在过去几十年中，临床试验已经确定了目前卵巢癌的治疗方法。紫杉醇联合铂类药物是目前首选的一线治疗药物，有令人鼓舞的数据支持剂量密集或腹腔内药物给药。未来的试验将确定生物制剂和疫苗治疗的作用及其对生活质量的影响。
